Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Boehringer Ingelheim
Daiichi Sankyo

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206353

« Back to Dashboard

NDA 206353 describes EVOTAZ, which is a drug marketed by Bristol-myers Squibb and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the EVOTAZ profile page.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atazanavir sulfate; cobicistat profile page.
Summary for 206353
Applicant:Bristol-myers Squibb
Ingredient:atazanavir sulfate; cobicistat
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 206353
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353 NDA E.R. Squibb & Sons, L.L.C. 0003-3641 0003-3641-11 30 TABLET in 1 BOTTLE (0003-3641-11)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 300MG BASE;150MG
Approval Date:Jan 29, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 27, 2017
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ SubscribePatent Expiration:Dec 20, 2017Product Flag?Substance Flag?Delist Request?Y
Patent:➤ SubscribePatent Expiration:Jun 21, 2019Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.